Table 3.
Univariable factors associated with shorter event‐free survival (EFS) and overall survival (OS) among patients treated with ibrutinib
| Characteristic | EFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | |
| Age at ibrutinib per 10 y increase | 1.11 (0.87‐1.41) | .41 | 1.32 (0.97‐1.81) | .08 |
| Female sex | 1.37 (0.82‐2.29) | .22 | 1.66 (0.88‐3.14) | .12 |
| Rai Stage (reference Rai 0) | .73 | .40 | ||
| Rai I/II | 0.72 (0.32‐1.61) | 0.55 (0.19‐1.64) | ||
| Rai III/IV | 0.84 (0.42‐1.70) | 0.96 (0.39‐2.34) | ||
| IGHV unmutated | 1.03 (0.55‐1.93) | .92 | 0.84 (0.38‐1.90) | .68 |
| High‐risk FISH (del11q and del17p) | 0.98 (0.58‐1.66) | .94 | 1.15 (0.59‐2.24) | .68 |
| TP53 disruption (del17p or TP53 mutation) | 1.67 (0.96‐2.91) | .07 | 2.26 (1.14‐4.50) | .02 |
| Reduced initial dose (<420 mg daily) | 1.00 (0.61‐1.64) | .99 | 1.22 (0.64‐2.30) | .55 |
| <2.5 mg/kg/d initial dose | 1.50 (0.85‐2.67) | .17 | 1.50 (0.70‐3.21) | .29 |
| Temporary dose interruption for any reason** | 2.23 (1.27‐3.91) | .005 | 2.15 (1.08‐4.29) | .03 |
**
Time dependent variable set up as time to first occurrence.
Bold indicates P‐value < .05